A review of asthma care in 50 general practices in Bedfordshire, United Kingdom
- PMID: 30050083
- PMCID: PMC6062519
- DOI: 10.1038/s41533-018-0093-7
A review of asthma care in 50 general practices in Bedfordshire, United Kingdom
Abstract
The United Kingdom (UK) National Review of Asthma Deaths (NRAD) (2011-2014) identified a number of contributory risk factors which had not previously been recognized by those caring for people with asthma. Only one of the 19 NRAD recommendations has so far been implemented nationally, and that only partially, and as yet systems are not in place to identify patients at risk of attacks and dying from asthma. In 2015/2016 Bedfordshire Clinical Commissioning Group (CCG) in England, UK, initiated a quality asthma audit of people with asthma to identify some of the risk factors identified in the NRAD report with the aim of optimizing patient care. Fifty (89%) of the General Practices caring for 415,152 patients (27,587 diagnosed with asthma (prevalence 7%; range 4-12%)), participated and the results identified a wide variation in process of care and presence of risk factors including: excess short acting reliever and insufficient preventer prescriptions, failure to issue personal asthma action plans, and to perform annual reviews or check inhaler technique. Identification of these patients involved high-intensity input by trained asthma nurses using sophisticated data extraction software. GP computer systems used in primary care currently do not have the functionally, without the need for manual audit, to implement the NRAD recommendations, starting with the identification of patients at risk. Modifications to existing systems within both primary and secondary care are required in order to prevent unnecessary deaths related to asthma. There is a pressing need to move towards a more pro-active model of care.
Conflict of interest statement
M.L.L. has received reimbursements for attending symposia, fees for speaking, fees for consulting from AstraZeneca, Boehringer Ingelheim, Chiesi, TEVA, NAPP Pharmaceuticals, SOAR Beyond, Clement Clarke International and NSHI. J.H. has received reimbursements for attending symposia, fees for speaking, organizing educational events, funds for research or fees for consulting from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Mundipharma, Novartis, Pfizer, Teva and Zentiva. I.P. is an employee of NSHI Ltd. E.Mc.K. is the Managing Director of NSHI Ltd. The remaining authors declare no competing interests..
Figures






References
-
- Royal College of Physicians. Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry report http://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-fu... (2014).
-
- British Thoracic Society, Scottish Intercollegiate Guideline Network. SIGN 153 - The British Guideline on the Management of Asthma https://www.brit-thoracic.org.uk/document-library/clinical-information/a... (2016).
-
- Global Initiative for Asthma. The Global Strategy for Asthma Management and Prevention http://www.ginasthma.org/ (2017).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical